A Study of LY2875358 in Participants With Advanced Cancer

NCT01287546 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: LY2875358
DRUG: LY2875358 + erlotinib
DRUG: LY2875358 at Part A highest dose
DRUG: LY2875358 at Part A highest dose + trametinib

Sponsor

Eli Lilly and Company